Diffuse Pleural Mesothelioma (MSK, 2024)

Overview

Single-center cohort of 290 patients with diffuse pleural mesothelioma (PLMESO) profiled by MSK-IMPACT at Memorial Sloan Kettering Cancer Center (January 2014–January 2021). A subset of 210 patients (72%) with sufficient tumor purity was analyzed for LOH using FACETS to identify a genomic near-haploidization (GNH) subset. Data deposited in cBioPortal as plmeso_msk_2024. PMID:38630790

Composition

  • 290 patients with DPM profiled by MSK-IMPACT; 210 evaluable for LOH analysis (≥20% tumor purity). PMID:38630790
  • 10 GNH cases (4.8%) in the primary cohort; 4 additional in a 105-patient validation cohort. PMID:38630790
  • Demographics: majority male (73%), median age 70 years; GNH patients younger (median 58 years). PMID:38630790
  • Cancer type: PLMESO — diffuse pleural mesothelioma. PMID:38630790

Assays / panels (linked)

Papers using this cohort

  • PMID:38630790 — Diffuse pleural mesotheliomas with genomic near-haploidization: a newly recognized subset with distinct clinical, histologic, and molecular features.

Notable findings derived from this cohort

  • GNH prevalence: 4.8% (10/210 evaluable), similar to TCGA-ICGC rate of 3.2%. GNH patients were younger (58 vs. 71 years, P=0.008) and had less occupational asbestos exposure (20% vs. 58.3%, P=0.02). PMID:38630790
  • 80% of GNH DPMs were biphasic vs. 15% of non-GNH (P<0.0001). PMID:38630790

Sources

This page was processed by entity-page-writer on 2026-04-11.